Latest Ratios: P/E Ratio -12.7x · EV/EBITDA N/A · ROE -7.6%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $3.5B | $2.1B | $67M | $89M | $482M | $2.0B |
| Enterprise Value | $1.4B | $3.5B | $2.1B | $87M | $29M | $114M | $2.0B |
| P/E Ratio → | -12.72 | — | — | — | — | — | — |
| P/S Ratio | 3.06 | 8.18 | 6.77 | 0.33 | 0.38 | 2.27 | 11.43 |
| P/B Ratio | 4.13 | 11.35 | 8.43 | 0.29 | 0.35 | 1.24 | 467.16 |
| P/FCF | — | 245.23 | — | — | — | — | — |
| P/OCF | 42.38 | 105.10 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 8.20 | 6.87 | 0.43 | 0.12 | 0.54 | 11.07 |
| EV / EBITDA | — | 261.19 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | 245.80 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 69.7% | 69.7% | 63.6% | 44.4% | -11.4% | -7.8% | 2.2% |
| Operating Margin | -2.8% | -2.8% | -7.6% | -89.2% | -284.5% | -210.3% | -134.9% |
| Net Profit Margin | -4.9% | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | -134.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -7.6% | -7.6% | -22.1% | -73.0% | -171.1% | -125.0% | -5500.0% |
| ROA | -4.5% | -4.5% | -12.5% | -36.5% | -99.9% | -60.9% | -95.9% |
| ROIC | -3.0% | -3.0% | -6.6% | -61.4% | -468.4% | — | — |
| ROCE | -3.0% | -3.0% | -6.4% | -47.5% | -156.4% | -141.4% | -135.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.47 | 0.53 | 0.30 | 0.08 | 9.86 |
| Debt / EBITDA | 8.43 | 8.43 | — | — | — | — | — |
| Net Debt / Equity | — | 0.03 | 0.13 | 0.09 | -0.24 | -0.95 | -14.79 |
| Net Debt / EBITDA | 0.61 | 0.61 | — | — | — | — | — |
| Debt / FCF | — | 0.57 | — | — | — | — | — |
| Interest Coverage | -7.32 | -7.32 | -16.36 | — | -142.66 | -85.56 | -96.55 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.46 | 2.46 | 3.61 | 3.10 | 1.47 | 4.77 | 2.37 |
| Quick Ratio | 2.34 | 2.34 | 3.42 | 2.95 | 1.38 | 4.44 | 2.03 |
| Cash Ratio | 1.57 | 1.57 | 2.58 | 2.21 | 0.95 | 3.95 | 1.47 |
| Asset Turnover | — | 0.82 | 0.73 | 0.48 | 0.43 | 0.38 | 0.71 |
| Inventory Turnover | 9.27 | 9.27 | 10.43 | 12.82 | 19.13 | 6.84 | 7.02 |
| Days Sales Outstanding | — | 63.49 | 44.97 | 59.13 | 67.41 | 45.69 | 65.81 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | 0.4% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $27M | $27M | $24M | $10M | $3M | $6M |
Includes 30+ ratios · 6 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WGS stock.
GeneDx Holdings Corp.'s current P/E ratio is -12.7x. This places it at the 50th percentile of its historical range.
GeneDx Holdings Corp.'s return on equity (ROE) is -7.6%. The historical average is -79.8%.
Based on historical data, GeneDx Holdings Corp. is trading at a P/E of -12.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
GeneDx Holdings Corp. has 69.7% gross margin and -2.8% operating margin.
GeneDx Holdings Corp.'s Debt/EBITDA ratio is 8.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Persistent operating losses and cash burn
Metrics are mathematically derived from official filings.
Turnaround Multiples Price Skepticism Not Growth
Based on reported figures, WGS trades at a trailing P/E of -13.96 and a forward P/E of 518.70, with P/S of 3.36 and P/B of 4.53, a configuration that signals the market is pricing sustained profitability as uncertain rather than imminent.
The negative trailing P/E reflects GAAP losses, so earnings-based valuation is not meaningful today, and the extreme forward P/E of 518.70 implies that the consensus earnings base remains near breakeven. Relative to peers, the P/S of 3.36 sits well below the P/B-driven premiums of PACB and NTRA, suggesting the market values WGS more as a revenue-generating lab than as a high-multiple data platform. Investors should monitor whether the Q4 adjusted net income step-up embedded in guidance is achieved, since it is the principal input that would justify a shift to earnings-based multiples.
Gross Margin Strength Masked by Operating Losses
As reported in quarterly statements, WGS's gross margin expanded from 60.9% in Q2 2024 to 69.9% in Q3 2026, yet the operating margin of -8.5% in Q3 2026 shows that operating expenses still absorb the gross profit.
The gross margin trajectory is the most encouraging element of the profitability profile, and it compares favorably with peer Natera's 64.8%, suggesting a higher-value test mix or improved reimbursement realization. However, the operating margin has swung from -25.6% in Q1 2026 to -8.5% in Q3 2026, and the path toward breakeven depends on continued SG&A discipline rather than further gross margin gains. Net margin of -10.0% in Q3 2026 remains heavily influenced by non-operating and one-time items, so operating margin is the more reliable gauge of earning power until those items are isolated.
Returns Negative but Improving from Trough
Based on reported ratios, ROIC improved from -5.7% in Q1 2026 to -2.2% in Q3 2026 and ROE from -22.5% to -5.0%, indicating the capital base is being used more productively though still destroying value.
The return trend is directionally positive, but the sustained negative ROIC means the company is not yet earning its cost of capital on invested funds. ROE's recovery is partly a function of equity rebuilding, which lifted the denominator, so the ROE improvement should not be read purely as operational progress. Relative to peer CDNA, which generates a positive 34.1% ROE, WGS remains structurally behind, and the gap is likely to persist until operating margins turn positive.
Debt Build Outpacing Equity Recovery
According to reported quarterly figures, WGS's debt-to-equity ratio rose from 0.39 in Q3 2025 to 0.88 in Q3 2026, while interest coverage remains negative at -5.91, meaning operating earnings do not yet cover interest expense.
The rise in leverage over the past year suggests the balance sheet is being funded increasingly by borrowing while the company continues to burn cash, which warrants close attention. Negative interest coverage indicates that debt service currently depends on the cash reserve rather than operating income, and the D/EBITDA ratio is unavailable in recent quarters, limiting a complete assessment. Investors should monitor refinancing terms and whether leverage stabilizes as operating losses narrow.
Working Capital Cycle Lengthening Under Pressure
Based on reported figures, WGS's cash conversion cycle stretched from 42 days in Q1 2025 to 104 days in Q3 2026, driven primarily by a rise in days inventory outstanding to 66 and a decline in days payables to 11.
The lengthening cycle is a notable negative signal, as it implies more capital is tied up in inventory and receivables while supplier financing has contracted. The sharp drop in DPO from 37 to 11 days suggests the company has less supplier credit to lean on, which increases the working capital burden on operating cash flow. This pattern is consistent with the working capital drag observed in prior cash flow findings and warrants monitoring of receivable collection timing.
Peer Comparison Flatters Gross Margin Narrative
Based on reported ratios, the most commonly misapplied metric for WGS is gross margin, which as reported stands near 69.9% in Q3 2026 but tells little about earning power for a lab whose costs sit largely in fixed operating expense.
Gross margin is often read as proof of a scalable diagnostic franchise, yet for WGS the gap between a 69.9% gross margin and an operating margin of -8.5% shows that sequencing economics do not translate into profit without SG&A leverage. Analysts should instead anchor on operating margin trajectory and cash conversion, adjusting for stock-based compensation of $8.3M in Q3 2026 to judge the underlying cash burn. This suggests the gross margin headline may overstate the near-term investment case until operating expense discipline is demonstrated.